Susannah Gray - 19 May 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: Director
Issuer ticker: TBPH
Reported as of: 19 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2025, 19:13:00 UTC
Prior SEC filing: 20 Aug 2024
Next SEC filing: 18 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Susannah Gray filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 21 May 2025.

Key facts

This page summarizes Susannah Gray's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 May 2025, 19:13.

Change

Previous filing in this sequence was filed on 20 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001833453 Primary reporting owner

GRAY SUSANNAH

Relationship: Director
Address: C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Signature date: 21 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +10,649
Change %: +34%
Price: $0.000000
Shares after: 42,137
Date: 19 May 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBPH transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +24,258
Change %
Price: $0.000000
Shares after: 24,258
Date: 19 May 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 24,258
Exercise price: $9.39
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.